Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...
The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.
Libtayo was approved by the US Food and Drug Administration (FDA) as a first-line (1L) therapy for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. On World ...
Arm 1 will administer Libtayo on day 5. The Company plans to ... MAIA expects to conduct the trials in the U.S. and select countries in Europe and Asia. MAIA recently announced an amended clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results